论文部分内容阅读
Endralazine(6-苯甲酰基-3-联胺5、6、7、S-四氢吡啶-4、3-C 吡啶,BQ22-708)是一种双吡啶衍生物。在结构上与肼苯哒嗪有关。其代谢主要通过与内源性酮结合形成联胺,而与病人的乙酰化能力无关。在高血压病人的研究中已证明 Endralazine 是有效的动脉扩张剂。本文报道慢性难治性心力衰竭病人口服 Endralazine 后的急性血流动力学效应。方法:10例病程在3月以上的慢性充血性心力衰竭病人。男性9例,女性1例,平均62岁(36～75
Endralazine (6-benzoyl-3-hydrazine 5,6,7, S-tetrahydropyridine-4,3-C pyridine, BQ22-708) is a bipyridine derivative. In the structure and hydralazine related. Its metabolism is mainly linked to endogenous ketones to form hydrazine, but not with the patient’s ability to acetylate. Endralazine has been shown to be a potent arterial vasodilator in studies of hypertensive patients. This article reports the acute hemodynamic effects of oral Endralazine in patients with chronic refractory heart failure. Methods: 10 patients with chronic congestive heart failure over 3 months. There were 9 males and 1 females, with an average age of 62 (36-75)